NCT00226915View on ClinicalTrials.gov

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

637

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions
DRUG

Paclitaxel+Carboplatin

Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles

DRUG

Paclitaxel+Carboplatin

Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles

Trial Locations (1)

Unknown

National Cancer Center Hospital, Chuo-ku

All Listed Sponsors
lead

Japanese Gynecologic Oncology Group

OTHER

NCT00226915 - Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | Biotech Hunter | Biotech Hunter